[177Lu]3BP-6146

N/A

Report date: 2025/11/14 09:32:42

NME

Base Information

Drug Name[177Lu]3BP-6146

Drug Alias Name[177Lu]3BP-6146

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionUrokinase plasminogen activator surface receptor modulators

TargetsUrokinase plasminogen activator surface receptor

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator Companies3B Pharmaceuticals GmbH

China Registration ClassN/A

Develop Information

Active Companies3B Pharmaceuticals GmbH

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A